Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Gains New Commercial Drug Orgovyx In Deal With Myovant

Deal Brings Pfizer Another Prostate Cancer Offering

Executive Summary

Myovant's Orgovyx was just approved by the US FDA for prostate cancer and could be approved soon for two women's health indications. 

You may also be interested in...



Myovant Expects Gradual Growth For Myfembree With Endometriosis Approval

Myovant and partner Pfizer have expected a slow ramp for Myfembree in uterine fibroids and new indication endometriosis as they build awareness and grow the market for the GnRH antagonist class.

Myovant/Pfizer Launch Myfembree With An Emphasis On Building Uterine Fibroid Awareness

Myovant CEO David Marek talked to Scrip about why the companies believe patients and physicians will choose Myfembree over AbbVie's Oriahnn.

Big Pharma Holds Steady With One-Third Of Novel Agents Approved In US In 2020

Gilead and Roche ended the year involved in three novel agents apiece, thanks to a combination of internal research and external licensing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC143557

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel